- Previous Close
12.91 - Open
12.96 - Bid 12.89 x 43500
- Ask 12.93 x 40000
- Day's Range
12.91 - 13.05 - 52 Week Range
10.69 - 14.34 - Volume
708 - Avg. Volume
60,373 - Market Cap (intraday)
28.208B - Beta (5Y Monthly) 0.34
- PE Ratio (TTM)
40.25 - EPS (TTM)
0.32 - Earnings Date Feb 4, 2025
- Forward Dividend & Yield 0.32 (2.45%)
- Ex-Dividend Date Dec 9, 2024
- 1y Target Est
13.93
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
www.coloplast.com16,639
Full Time Employees
September 30
Fiscal Year Ends
Sector
Medical Instruments & Supplies
Industry
Recent News: CLPBY
View More
Performance Overview: CLPBY
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CLPBY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CLPBY
View MoreValuation Measures
Market Cap
29.16B
Enterprise Value
32.25B
Trailing P/E
40.30
Forward P/E
34.01
PEG Ratio (5yr expected)
3.36
Price/Sales (ttm)
7.53
Price/Book (mrq)
11.37
Enterprise Value/Revenue
8.43
Enterprise Value/EBITDA
26.86
Financial Highlights
Profitability and Income Statement
Profit Margin
18.69%
Return on Assets (ttm)
9.49%
Return on Equity (ttm)
28.67%
Revenue (ttm)
27.03B
Net Income Avi to Common (ttm)
5.05B
Diluted EPS (ttm)
0.32
Balance Sheet and Cash Flow
Total Cash (mrq)
788M
Total Debt/Equity (mrq)
126.12%
Levered Free Cash Flow (ttm)
-647.75M
Research Analysis: CLPBY
View MoreCompany Insights: CLPBY
CLPBY does not have Company Insights
Research Reports: CLPBY
View MoreColoplast: Inclusion of Kerecis for Medicare Reimbursement Bodes Well
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
RatingPrice TargetColoplast's Luja and Helo Products Offer Revolutionary Innovation
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
RatingPrice TargetColoplast: Stays a Step Ahead of Competition Thanks to Innovative New Products
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
RatingPrice TargetColoplast Continues To Work Through Near-Term Headwinds
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
RatingPrice Target